blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2903636

EP2903636 - IMMUNOGENIC COMPOSITIONS [Right-click to bookmark this link]
StatusPatent revoked
Status updated on  05.12.2024
Database last updated on 03.04.2025
FormerThe patent has been granted
Status updated on  15.06.2018
FormerGrant of patent is intended
Status updated on  05.04.2018
FormerExamination is in progress
Status updated on  20.01.2017
Most recent event   Tooltip06.12.2024Revocation of patentpublished on 08.01.2025  [2025/02]
Applicant(s)For all designated states
GlaxoSmithKline Biologicals S.A.
Rue de l'Institut, 89
1330 Rixensart / BE
[2018/29]
Former [2015/33]For all designated states
GlaxoSmithKline Biologicals S.A.
rue de l'Institut, 89
1330 Rixensart / BE
Inventor(s)01 / CONTORNI, Mario
c/o Novartis Vaccines&Diagnostics S.r.l.
Via Fiorentina 1
53100 Siena / IT
02 / GRANDI, Guido
c/o Novartis Vaccines&Diagnostics S.r.l.
Via Fiorentina 1
53100 Siena / IT
03 / MAIONE, Domenico
c/o Novartis Vaccines&Diagnostics S.r.l.
Via Fiorentina 1
53100 Siena / IT
04 / MARGARIT Y ROS, Immaculada
c/o Novartis Vaccines&Diagnostics S.r.l.
Via Fiorentina 1
53100 Siena / IT
 [2015/33]
Representative(s)Racine, Sophie Christiane Carol, et al
GSK
Legal & Compliance - Global Patents
79 New Oxford Street
London WC1A 1DG / GB
[N/P]
Former [2018/29]Evans, Stephen John Eves, et al
GlaxoSmithKline
Global Patents CN925.1
980 Great West Road
Brentford, Middlesex TW8 9GS / GB
Former [2015/33]Evans, Stephen John Eves, et al
Novartis
Vaccines and Diagnostics S.r.l.
Intellectual Property
Via Fiorentina, 1
53100 Siena / IT
Application number, filing date13795176.003.10.2013
[2015/33]
WO2013EP70647
Priority number, dateUS201261744880P03.10.2012         Original published format: US 201261744880 P
US201361799123P15.03.2013         Original published format: US 201361799123 P
[2015/33]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2014053607
Date:10.04.2014
Language:EN
[2014/15]
Type: A1 Application with search report 
No.:EP2903636
Date:12.08.2015
Language:EN
The application published by WIPO in one of the EPO official languages on 10.04.2014 takes the place of the publication of the European patent application.
[2015/33]
Type: B1 Patent specification 
No.:EP2903636
Date:18.07.2018
Language:EN
[2018/29]
Search report(s)International search report - published on:EP10.04.2014
ClassificationIPC:A61K39/00, A61K39/02, A61K39/05, A61K39/08, A61K39/09, A61K39/13
[2015/33]
CPC:
A61K39/092 (EP,US); A61K39/0018 (EP,US); A61K39/05 (EP,US);
A61K39/08 (EP,US); A61K39/099 (EP,US); A61K39/12 (EP,US);
A61K39/13 (EP,US); A61K47/6415 (EP,US); A61K47/646 (EP,US);
A61K9/0019 (US); A61P11/00 (EP); A61P15/00 (EP);
A61P15/08 (EP); A61P19/02 (EP); A61P25/00 (EP);
A61P31/00 (EP); A61P31/04 (EP); A61P31/10 (EP);
A61P37/04 (EP); A61P7/00 (EP); C12N7/00 (US);
A61K2039/55 (US); A61K2039/55505 (EP,US); A61K2039/6037 (EP,US);
A61K2039/70 (EP,US); C12N2770/32334 (EP,US); C12N2770/32634 (US);
Y02A50/30 (EP,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2015/33]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:IMMUNOGENE ZUSAMMENSETZUNGEN[2015/33]
English:IMMUNOGENIC COMPOSITIONS[2015/33]
French:COMPOSITIONS IMMUNOGÈNES[2015/33]
Entry into regional phase04.05.2015National basic fee paid 
04.05.2015Designation fee(s) paid 
04.05.2015Examination fee paid 
Examination procedure20.02.2015Amendment by applicant (claims and/or description)
04.05.2015Examination requested  [2015/33]
18.01.2017Despatch of a communication from the examining division (Time limit: M04)
23.05.2017Reply to a communication from the examining division
16.02.2018Despatch of a communication from the examining division (Time limit: M01)
13.03.2018Reply to a communication from the examining division
05.04.2018Communication of intention to grant the patent
06.06.2018Fee for grant paid
06.06.2018Fee for publishing/printing paid
06.06.2018Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  18.01.2017
Opposition(s)Opponent(s)01  18.04.2019  29.04.2019  ADMISSIBLE
Pfizer Inc.
66 Hudson Boulevard East
New York, NY 10001-2192 / US
Opponent's representative
Pfizer
European Patent Department
23-25 avenue du Docteur Lannelongue
75668 Paris Cedex 14 / FR
 [2023/27]
Former [2019/22]
Opponent(s)01  18.04.2019    ADMISSIBLE
Pfizer Inc.
235 East 42nd Street
New York, NY 10017 / US
Opponent's representative
Pfizer
European Patent Department
23-25 avenue du Docteur Lannelongue
75668 Paris Cedex 14 / FR
08.05.2019Invitation to proprietor to file observations on the notice of opposition
18.09.2019Reply of patent proprietor to notice(s) of opposition
11.08.2020Cancellation of oral proceeding that was planned for 23.09.2020
23.09.2020Date of oral proceedings
04.11.2021Date of oral proceedings
27.01.2022Despatch of minutes of oral proceedings
31.01.2022Despatch of interlocutory decision in opposition
21.11.2024Legal effect of revocation of patent [2025/02]
22.11.2024Despatch of communication that the patent will be revoked
Appeal following opposition07.04.2022Appeal received No.  T0711/22
07.04.2022Payment of appeal fee
10.06.2022Statement of grounds filed
21.11.2024Result of appeal procedure: revocation of the patent
22.11.2024Despatch of the decision of the Board of Appeal
16.03.2022Appeal received No.  T0711/22
16.03.2022Payment of appeal fee
10.06.2022Statement of grounds filed
21.11.2024Result of appeal procedure: revocation of the patent
22.11.2024Despatch of the decision of the Board of Appeal
21.11.2024Date of oral proceedings
Fees paidRenewal fee
07.10.2015Renewal fee patent year 03
07.10.2016Renewal fee patent year 04
10.10.2017Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU03.10.2013
AL18.07.2018
AT18.07.2018
CY18.07.2018
CZ18.07.2018
DK18.07.2018
EE18.07.2018
FI18.07.2018
HR18.07.2018
LT18.07.2018
LV18.07.2018
MC18.07.2018
MK18.07.2018
PL18.07.2018
PT18.07.2018
RO18.07.2018
RS18.07.2018
SE18.07.2018
SI18.07.2018
SK18.07.2018
SM18.07.2018
LU03.10.2018
MT03.10.2018
BG18.10.2018
NO18.10.2018
GR19.10.2018
CH31.10.2018
LI31.10.2018
IS18.11.2018
[2020/31]
Former [2020/28]AL18.07.2018
AT18.07.2018
CZ18.07.2018
DK18.07.2018
EE18.07.2018
FI18.07.2018
HR18.07.2018
LT18.07.2018
LV18.07.2018
MC18.07.2018
PL18.07.2018
PT18.07.2018
RO18.07.2018
RS18.07.2018
SE18.07.2018
SI18.07.2018
SK18.07.2018
SM18.07.2018
LU03.10.2018
MT03.10.2018
BG18.10.2018
NO18.10.2018
GR19.10.2018
CH31.10.2018
LI31.10.2018
IS18.11.2018
Former [2020/08]AL18.07.2018
AT18.07.2018
CZ18.07.2018
DK18.07.2018
EE18.07.2018
FI18.07.2018
HR18.07.2018
LT18.07.2018
LV18.07.2018
MC18.07.2018
PL18.07.2018
RO18.07.2018
RS18.07.2018
SE18.07.2018
SI18.07.2018
SK18.07.2018
SM18.07.2018
LU03.10.2018
MT03.10.2018
BG18.10.2018
NO18.10.2018
GR19.10.2018
CH31.10.2018
LI31.10.2018
IS18.11.2018
Former [2019/40]AL18.07.2018
AT18.07.2018
CZ18.07.2018
DK18.07.2018
EE18.07.2018
FI18.07.2018
HR18.07.2018
LT18.07.2018
LV18.07.2018
MC18.07.2018
PL18.07.2018
RO18.07.2018
RS18.07.2018
SE18.07.2018
SI18.07.2018
SK18.07.2018
SM18.07.2018
LU03.10.2018
BG18.10.2018
NO18.10.2018
GR19.10.2018
CH31.10.2018
LI31.10.2018
IS18.11.2018
Former [2019/37]AL18.07.2018
AT18.07.2018
CZ18.07.2018
DK18.07.2018
EE18.07.2018
FI18.07.2018
HR18.07.2018
LT18.07.2018
LV18.07.2018
MC18.07.2018
PL18.07.2018
RO18.07.2018
RS18.07.2018
SE18.07.2018
SI18.07.2018
SK18.07.2018
SM18.07.2018
LU03.10.2018
BG18.10.2018
NO18.10.2018
GR19.10.2018
IS18.11.2018
Former [2019/30]AL18.07.2018
AT18.07.2018
CZ18.07.2018
DK18.07.2018
EE18.07.2018
FI18.07.2018
HR18.07.2018
LT18.07.2018
LV18.07.2018
MC18.07.2018
PL18.07.2018
RO18.07.2018
RS18.07.2018
SE18.07.2018
SK18.07.2018
SM18.07.2018
LU03.10.2018
BG18.10.2018
NO18.10.2018
GR19.10.2018
IS18.11.2018
Former [2019/28]AL18.07.2018
AT18.07.2018
CZ18.07.2018
DK18.07.2018
EE18.07.2018
FI18.07.2018
HR18.07.2018
LT18.07.2018
LV18.07.2018
MC18.07.2018
PL18.07.2018
RO18.07.2018
RS18.07.2018
SE18.07.2018
SK18.07.2018
SM18.07.2018
BG18.10.2018
NO18.10.2018
GR19.10.2018
IS18.11.2018
Former [2019/26]AL18.07.2018
AT18.07.2018
CZ18.07.2018
DK18.07.2018
EE18.07.2018
FI18.07.2018
HR18.07.2018
LT18.07.2018
LV18.07.2018
PL18.07.2018
RO18.07.2018
RS18.07.2018
SE18.07.2018
SK18.07.2018
SM18.07.2018
BG18.10.2018
NO18.10.2018
GR19.10.2018
IS18.11.2018
Former [2019/24]AL18.07.2018
AT18.07.2018
CZ18.07.2018
EE18.07.2018
FI18.07.2018
HR18.07.2018
LT18.07.2018
LV18.07.2018
PL18.07.2018
RO18.07.2018
RS18.07.2018
SE18.07.2018
SK18.07.2018
BG18.10.2018
NO18.10.2018
GR19.10.2018
IS18.11.2018
Former [2019/22]AL18.07.2018
AT18.07.2018
CZ18.07.2018
FI18.07.2018
HR18.07.2018
LT18.07.2018
LV18.07.2018
PL18.07.2018
RO18.07.2018
RS18.07.2018
SE18.07.2018
BG18.10.2018
NO18.10.2018
GR19.10.2018
IS18.11.2018
Former [2019/12]AL18.07.2018
AT18.07.2018
FI18.07.2018
HR18.07.2018
LT18.07.2018
LV18.07.2018
PL18.07.2018
RS18.07.2018
SE18.07.2018
BG18.10.2018
NO18.10.2018
GR19.10.2018
IS18.11.2018
Former [2019/11]AT18.07.2018
FI18.07.2018
HR18.07.2018
LT18.07.2018
PL18.07.2018
RS18.07.2018
SE18.07.2018
BG18.10.2018
NO18.10.2018
GR19.10.2018
IS18.11.2018
Former [2019/10]AT18.07.2018
FI18.07.2018
LT18.07.2018
PL18.07.2018
RS18.07.2018
SE18.07.2018
BG18.10.2018
NO18.10.2018
GR19.10.2018
IS18.11.2018
Former [2019/08]FI18.07.2018
LT18.07.2018
NO18.10.2018
IS18.11.2018
Former [2019/07]LT18.07.2018
Cited inInternational search[A]WO9640242  (SMITHKLINE BEECHAM BIOLOG [BE], et al) [A] 1-50* claims 1-5 *;
 [I]EP0866133  (BRIGHAM & WOMENS HOSPITAL [US]) [I] 1,3-5,8,9,12,22-28,30-40,44-46 * page 12, line 24 - line 26; claim 1 *;
 [A]US2004202668  (BOUTRIAU DOMINIQUE [BE], et al) [A] 1-50 * claim 1 *;
 [XI]WO2006082527  (CHIRON SRL [IT], et al) [X] 46 * page 11, line 5 - line 14 * * page 13, line 7 - line 32 * * page 15, line 8 - line 12 * [I] 1-37,40-45,47,48;
 [XI]WO2012035519  (NOVARTIS AG [CH], et al) [X] 1-3,13,14,28,29,36-39,46 * claim 20 * [I] 8-12,22,23,30-35,47-50;
 [A]  - PALAZZI D L ET AL, "Use of type V group B streptococcal conjugate vaccine in adults 65-85 years old", JOURNAL OF INFECTIOUS DISEASES.JID, UNIVERSITY OF CHICAGO PRESS, CHICAGO, IL, (20040801), vol. 190, doi:10.1086/422010, ISSN 0022-1899, pages 558 - 564, XP002997497 [A] 1-50 * abstract *

DOI:   http://dx.doi.org/10.1086/422010
by applicantUS4356170
 EP0109942
 EP0372501
 EP0378881
 WO9101146
 EP0427347
 US5057540
 EP0471177
 EP0477508
 WO9317712
 WO9403208
 US5306492
 EP0594610
 EP0626169
 WO9517211
 WO9611711
 WO9633739
 WO9640795
 WO9640242
 US5614382
 WO9840100
 WO9842721
 WO9842375
 WO9858668
 WO9927960
 US5916588
 WO9940936
 WO9942130
 WO9944636
 WO9952549
 WO9962923
 WO0007621
 US6027733
 WO0023105
 WO0033882
 WO0038711
 US6090406
 WO0053221
 WO0056360
 WO0056365
 WO0061761
 US6146902
 US6207646
 WO0121207
 WO0121152
 US6239116
 WO0141800
 US6274144
 WO0172337
 WO0195935
 US6355271
 WO0226757
 US6429199
 WO02091998
 WO03009869
 WO03024480
 WO03024481
 WO03035836
 WO2004011027
 WO2004041157
 WO2004060308
 WO2004064759
 WO2005000346
 WO2006050341
 WO2006082527
 WO2006082530
 WO2008028956
 WO2008028957
 WO2009010877
 WO2009081276
 WO2012035519
    - PAOLETTI ET AL., J BIOL CHEM, (1990), vol. 265, pages 18278 - 83
    - WESSELS ET AL., J CLIN INVEST, (1990), vol. 86, pages 1428 - 33
    - PAOLETTI ET AL., INFECT IMMUN, (1992), vol. 60, pages 4009 - 14
    - PAOLETTI ET AL., J CLIN INVEST, (1992), vol. 89, pages 203 - 9
    - WESSELS ET AL., PROC NATL ACAD SCI USA, (1987), vol. 84, pages 9170 - 4
    - WANG ET AL., VACCINE, (2003), vol. 21, pages 1112 - 7
    - WESSELS ET AL., INFECT IMMUN, (1993), vol. 61, pages 4760 - 6
    - WESSELS ET AL., J INFECT DIS, (1995), vol. 171, pages 879 - 84
    - BAKER ET AL., J INFECT DIS, (2004), vol. 189, pages 1103 - 12
    - PAOLETTI; KASPER, EXPERT OPIN BIOL THER, (2003), vol. 3, pages 975 - 84
    - GUTTORMSEN ET AL., PROC NATL ACAD SCI USA., (20080331), vol. 105, no. 15, pages 5903 - 8
    - MICHON ET AL., CLIN VACCINE IMMUNOL., (200608), vol. 13, no. 8, pages 93 6 - 43
    - LEWIS ET AL., PNAS USA, (2004), vol. 101, pages 11123 - 8
    - WESSELS ET AL., INFECT IMMUN, (1989), vol. 57, pages 1089 - 94
    - RAMSAY ET AL., LANCET, (2001), vol. 357, no. 9251, pages 195 - 196
    - LINDBERG, VACCINE, (1999), vol. 17, no. 2, pages 28 - 36
    - BUTTERY; MOXON, JR COLL PHYSICIANS LOND, (2000), vol. 34, pages 163 - 68
    - AHMAD; CHAPNICK, INFECT DIS CLIN NORTH AM, (1999), vol. 13, pages 113 - 33
    - GOLDBLATT, J. MED. MICROBIOL., (1998), vol. 47, pages 563 - 7
    - DICK ET AL., Conjugate Vaccines, KARGER, (1989), vol. 10, pages 48 - 114
    - Hermanson Bioconjugae Techniques, ACADEMIC PRESS, (1996), ISBN 0123423368
    - ANONYMOUS, RESEARCH DISCLOSURE, (200201), page 453077
    - ANDERSON, INFECT IMMUN, (1983), vol. 39, no. 1, pages 233 - 238
    - ANDERSON ET AL., J CLIN INVEST, (1985), vol. 76, no. 1, pages 52 - 59
    - FALUGI ET AL., EUR J IMMUNOL, (2001), vol. 31, pages 3816 - 24
    - BARALDO ET AL., INFECT IMMUN, (2004), vol. 72, pages 4884 - 87
    - KUO ET AL., INFECT IMMUN, (1995), vol. 63, pages 2706 - 13
    - LEI ET AL., DEV BIOL (BASEL, (2000), vol. 103, pages 259 - 264
    - SESARDIC ET AL., BIOLOGICALS, (2001), vol. 29, pages 107 - 22
    - SESARDIC ET AL., BIOLOGICALS, (2002), vol. 30, pages 49 - 68
    - RAPPUOLI ET AL., TIBTECH, (1991), vol. 9, pages 232 - 238
    - LIAO ET AL., J INFECT DIS., (2012), vol. 205, pages 237 - 43
    - PAOLETTI ET AL., VACCINE, (2001), vol. 19, pages 2118 - 2126
    - GENNARO, Remington: The Science and Practice of Pharmacy. 20th edition,, (2000), ISBN 0683306472
    - PAOLETTI, VACCINE, (2001), vol. 19, no. 15-16, pages 2118 - 26
    - ALMEIDA; ALPAR, J. DRUG TARGETING, (1996), vol. 3, pages 455 - 467
    - AGARWAL; MISHRA, INDIAN JEXP BIOL, (1999), vol. 37, pages 6 - 16
    - JAKOBSEN ET AL., INFECT IMMUN, (2002), vol. 70, pages 1443 - 1452
    - BERGQUIST ET AL., APMIS, (1998), vol. 106, pages 800 - 806
    - BAUDNER ET AL., INFECT IMMUN, (2002), vol. 70, pages 4785 - 4790
    - UGOZZOLI ET AL., J LNFECT DIS, (2002), vol. 186, pages 1358 - 1361
    - NONY ET AL., VACCINE, (2001), vol. 27, pages 3645 - 51
    - POWELL & NEWMAN, Vaccine Design..., PLENUM, (1995), ISBN 030644867X
    - BARR, ADVANCED DRUG DELIVERY REVIEWS, (1998), vol. 32, pages 247 - 271
    - SJOLANDERET ET AL., ADVANCED DRUG DELIVERY REVIEWS, (1998), vol. 32, pages 321 - 338
    - NIIKURA ET AL., VIROLOGY, (2002), vol. 293, pages 273 - 280
    - LENZ ET AL., J IMMUNOL, (2001), vol. 166, pages 5346 - 5355
    - PINTO ET AL., J INFECT DIS, (2003), vol. 188, pages 327 - 338
    - GERBER ET AL., VIROL, (2001), vol. 75, pages 4752 - 4760
    - GLUCK ET AL., VACCINE, (2002), vol. 20, pages B10 - B16
    - KANDIMALLA ET AL., NUCLEIC ACIDS RESEARCH, (2003), vol. 31, pages 2393 - 2400
    - KRIEG, NATURE MEDICINE, (2003), vol. 9, pages 831 - 835
    - MCCLUSKIE ET AL., FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY, (2002), vol. 32, pages 179 - 185
    - KANDIMALLA ET AL., BIOCHEMICAL SOCIETY TRANSACTIONS, (2003), vol. 31, pages 654 - 658
    - BLACKWELL ET AL., J IMMUNOL, (2003), vol. 170, pages 4061 - 4068
    - KRIEG, TRENDS IMMUNOL, (2002), vol. 23, pages 64 - 65
    - KANDIMALLA ET AL., BBRC, (2003), vol. 306, pages 948 - 953
    - BHAGAT ET AL., BBRC, (2003), vol. 300, pages 853 - 861
    - BEIGNON ET AL., INFECT IMMUN, (2002), vol. 70, pages 3012 - 3019
    - PIZZA ET AL., VACCINE, (2001), vol. 19, pages 2534 - 2541
    - PIZZA ET AL., INT JMED MICROBIOL, (2000), vol. 290, pages 455 - 461
    - SCHARTON-KERSTEN ET AL., INFECT IMMUN, (2000), vol. 68, pages 5306 - 5313
    - RYAN ET AL., INFECT IMMUN, (1999), vol. 67, pages 6270 - 6280
    - PARTIDOS ET AL., IMMUNOL LETT, (1999), vol. 67, pages 209 - 216
    - PEPPOLONI ET AL., EXPERT REV VACCINES, (2003), vol. 2, pages 285 - 293
    - PINE ET AL., J CONTROL RELEASE, (2002), vol. 85, pages 263 - 270
    - DOMENIGHINI ET AL., MOL MICROBIOL, (1995), vol. 15, pages 1165 - 1167
    - SINGH ET AL., J CONT RELEASE, (2001), vol. 70, pages 267 - 276
    - ANDRIANOV ET AL., BIOMATERIALS, (1998), vol. 19, pages 109 - 115
    - PAYNE ET AL., ADV DRUG DELIVERY REVIEW, (1998), vol. 31, pages 185 - 196
    - STANLEY, CLIN EXP DERMATOL, (2002), vol. 27, pages 571 - 577
    - JONES, CURR OPIN INVESTIG DRUGS, (2003), vol. 4, pages 214 - 218
    - HENNINGS ET AL., J INFECT DIS., (20010301), vol. 183, no. 7, pages 1138 - 42
    - GLEZEN; ALPERS, CLIN. INFECT. DIS., (1999), vol. 28, pages 219 - 224
    - MADOFF ET AL., J CLIN INVEST, (1994), vol. 94, pages 286 - 92
    - PAOLETTI ET AL., INFECT IMMUN, (1994), vol. 62, pages 3236 - 43
    - FABBRINI ET AL., J IMMUN METHODS, (2012), vol. 378, pages 11 - 19
 US20070894107
 GB20110021301
OppositionWO2006082530
 WO2009081276
 WO2012035519
    - "CHAPTER 21", Plotkin ET AL, Vaccines, (20040000), pages 471 - 528, ISBN 0-7216-9688-0, XP055583972
    - "CHAPTER 24", Plotkin, Et Al, Vaccines, (20040000), pages 625 - 649, XP055583982
    - "CHAPTER 13", Plotkin, Et Al, Vaccines, (20040000), pages 211 - 228, XP055583984
    - "CHAPTER 27", Plotkin, Et Al, Vaccines, (20040000), pages 745 - 781, XP055583989
    - "Recommended Immunization Schedules for Persons Aged 0 Through 18 Years __ United States", Morbidity Mortaility Weekly Report., (20120210), vol. 61, no. 5, pages 1 - 4, XP055583992
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.